SG11202108480UA - Compositions useful in treatment of krabbe disease - Google Patents
Compositions useful in treatment of krabbe diseaseInfo
- Publication number
- SG11202108480UA SG11202108480UA SG11202108480UA SG11202108480UA SG11202108480UA SG 11202108480U A SG11202108480U A SG 11202108480UA SG 11202108480U A SG11202108480U A SG 11202108480UA SG 11202108480U A SG11202108480U A SG 11202108480UA SG 11202108480U A SG11202108480U A SG 11202108480UA
- Authority
- SG
- Singapore
- Prior art keywords
- treatment
- compositions useful
- krabbe disease
- krabbe
- disease
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2468—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on beta-galactose-glycoside bonds, e.g. carrageenases (3.2.1.83; 3.2.1.157); beta-agarase (3.2.1.81)
- C12N9/2471—Beta-galactosidase (3.2.1.23), i.e. exo-(1-->4)-beta-D-galactanase
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/30—Vector systems having a special element relevant for transcription being an enhancer not forming part of the promoter region
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01046—Galactosylceramidase (3.2.1.46)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962810708P | 2019-02-26 | 2019-02-26 | |
| US201962817482P | 2019-03-12 | 2019-03-12 | |
| US201962877707P | 2019-07-23 | 2019-07-23 | |
| US201962916652P | 2019-10-17 | 2019-10-17 | |
| PCT/US2020/019794 WO2020176562A1 (en) | 2019-02-26 | 2020-02-26 | Compositions useful in treatment of krabbe disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202108480UA true SG11202108480UA (en) | 2021-09-29 |
Family
ID=69941503
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202108480UA SG11202108480UA (en) | 2019-02-26 | 2020-02-26 | Compositions useful in treatment of krabbe disease |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20220118108A1 (es) |
| EP (1) | EP3931337A1 (es) |
| JP (1) | JP2022525848A (es) |
| KR (1) | KR20210132095A (es) |
| CN (1) | CN114040980A (es) |
| AU (1) | AU2020229772A1 (es) |
| BR (1) | BR112021016566A2 (es) |
| CA (1) | CA3130055A1 (es) |
| CL (1) | CL2021002248A1 (es) |
| CO (1) | CO2021011090A2 (es) |
| IL (1) | IL285776A (es) |
| MX (1) | MX2021010266A (es) |
| PE (1) | PE20212072A1 (es) |
| SG (1) | SG11202108480UA (es) |
| TW (1) | TW202045728A (es) |
| WO (1) | WO2020176562A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230023637A (ko) * | 2020-05-12 | 2023-02-17 | 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 | 크라베병의 치료에 유용한 조성물 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5139941A (en) | 1985-10-31 | 1992-08-18 | University Of Florida Research Foundation, Inc. | AAV transduction vectors |
| US5436146A (en) | 1989-09-07 | 1995-07-25 | The Trustees Of Princeton University | Helper-free stocks of recombinant adeno-associated virus vectors |
| US6268213B1 (en) | 1992-06-03 | 2001-07-31 | Richard Jude Samulski | Adeno-associated virus vector and cis-acting regulatory and promoter elements capable of expressing at least one gene and method of using same for gene therapy |
| US5869305A (en) | 1992-12-04 | 1999-02-09 | The University Of Pittsburgh | Recombinant viral vector system |
| US6204059B1 (en) | 1994-06-30 | 2001-03-20 | University Of Pittsburgh | AAV capsid vehicles for molecular transfer |
| US5741683A (en) | 1995-06-07 | 1998-04-21 | The Research Foundation Of State University Of New York | In vitro packaging of adeno-associated virus DNA |
| US6093570A (en) | 1995-06-07 | 2000-07-25 | The University Of North Carolina At Chapel Hill | Helper virus-free AAV production |
| US6548286B1 (en) | 1997-04-14 | 2003-04-15 | Cell Genesys, Inc. | Methods for increasing the efficiency of recombinant AAV product |
| EP1080218A1 (en) | 1998-05-27 | 2001-03-07 | University of Florida | Method of preparing recombinant adeno-associated virus compositions by using an iodixanol gradient |
| AU780231B2 (en) | 1998-11-10 | 2005-03-10 | University Of North Carolina At Chapel Hill, The | Virus vectors and methods of making and administering the same |
| ES2478635T3 (es) | 1999-08-09 | 2014-07-22 | Targeted Genetics Corporation | Incremento de la expresión de una secuencia de nucleótidos heteróloga monocatenaria de vectores virales recombinantes diseñando la secuencia de modo que forma pares de bases intracatenarios |
| ATE438414T1 (de) | 2000-06-01 | 2009-08-15 | Univ North Carolina | Verfahren und zusammensetzungen zur kontrollierter abgabe von rekombinant parvovirus vektoren |
| ES2258601T3 (es) | 2001-11-13 | 2006-09-01 | The Trustees Of The University Of Pennsylvania | Un metodo para la identificacion de las secuencias desconocidas del virus adeno-asociado (vaa) y un kit para el metodo. |
| US20070015238A1 (en) | 2002-06-05 | 2007-01-18 | Snyder Richard O | Production of pseudotyped recombinant AAV virions |
| EP2434420A3 (en) | 2003-08-01 | 2012-07-25 | Dna Twopointo Inc. | Systems and methods for biopolymer engineering |
| US8005620B2 (en) | 2003-08-01 | 2011-08-23 | Dna Twopointo Inc. | Systems and methods for biopolymer engineering |
| CN1856576B (zh) | 2003-09-30 | 2011-05-04 | 宾夕法尼亚州立大学托管会 | 腺伴随病毒(aav)进化支、序列、含有这些序列的载体及它们的应用 |
| EP2359865B1 (en) | 2005-04-07 | 2013-10-02 | The Trustees of The University of Pennsylvania | Method of increasing the function of an AAV vector |
| WO2006132118A1 (ja) | 2005-06-09 | 2006-12-14 | Matsushita Electric Industrial Co., Ltd. | 振幅誤差補償装置及び直交度誤差補償装置 |
| EP2007795B1 (en) | 2006-03-30 | 2016-11-16 | The Board Of Trustees Of The Leland Stanford Junior University | Aav capsid proteins |
| WO2010138263A2 (en) | 2009-05-28 | 2010-12-02 | University Of Massachusetts | Novel aav 's and uses thereof |
| AU2011238708B2 (en) | 2010-03-29 | 2016-02-11 | The Trustees Of The University Of Pennsylvania | Pharmacologically Induced Transgene Ablation system |
| US8927514B2 (en) | 2010-04-30 | 2015-01-06 | City Of Hope | Recombinant adeno-associated vectors for targeted treatment |
| FR2977562B1 (fr) | 2011-07-06 | 2016-12-23 | Gaztransport Et Technigaz | Cuve etanche et thermiquement isolante integree dans une structure porteuse |
| EP2882284B1 (en) * | 2012-08-07 | 2017-11-15 | Chiesi Farmaceutici S.p.A. | Animal model of krabbe's disease |
| WO2015012924A2 (en) | 2013-04-29 | 2015-01-29 | The Trustees Of The University Of Pennsylvania | Tissue preferential codon modified expression cassettes, vectors containing same, and use thereof |
| DK3198018T3 (da) | 2014-09-24 | 2021-03-01 | Hope City | Vektorvarianter af adenoassocieret virus til højeffektiv genomredigering og fremgangsmåder dertil |
| CN106715058A (zh) | 2014-09-26 | 2017-05-24 | 泰拉丁公司 | 抓取手爪 |
| JP2020505317A (ja) * | 2017-01-20 | 2020-02-20 | ユニバーシティ オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション | 臍帯血移植（ｕｃｂｔ）および増加したガラクトセレブロシダーゼの発現によるクラッベ病の処置 |
| FI3589730T3 (fi) | 2017-02-28 | 2024-02-22 | Univ Pennsylvania | Kladin f adenoassosioitunut virus (aav) -vektori ja sen käyttötapoja |
| WO2018160852A1 (en) | 2017-03-03 | 2018-09-07 | Cook Medical Technologies, LLC | Rapid exchange multiple catheter system |
| AU2018346105C1 (en) * | 2017-10-03 | 2023-10-12 | Prevail Therapeutics, Inc. | Gene therapies for lysosomal disorders |
-
2020
- 2020-02-26 WO PCT/US2020/019794 patent/WO2020176562A1/en active Application Filing
- 2020-02-26 PE PE2021001391A patent/PE20212072A1/es unknown
- 2020-02-26 CN CN202080017113.6A patent/CN114040980A/zh active Pending
- 2020-02-26 TW TW109106249A patent/TW202045728A/zh unknown
- 2020-02-26 AU AU2020229772A patent/AU2020229772A1/en active Pending
- 2020-02-26 CA CA3130055A patent/CA3130055A1/en active Pending
- 2020-02-26 KR KR1020217029570A patent/KR20210132095A/ko unknown
- 2020-02-26 MX MX2021010266A patent/MX2021010266A/es unknown
- 2020-02-26 US US17/433,195 patent/US20220118108A1/en active Pending
- 2020-02-26 JP JP2021549986A patent/JP2022525848A/ja active Pending
- 2020-02-26 SG SG11202108480UA patent/SG11202108480UA/en unknown
- 2020-02-26 BR BR112021016566A patent/BR112021016566A2/pt unknown
- 2020-02-26 EP EP20713474.3A patent/EP3931337A1/en active Pending
-
2021
- 2021-08-22 IL IL285776A patent/IL285776A/en unknown
- 2021-08-24 CO CONC2021/0011090A patent/CO2021011090A2/es unknown
- 2021-08-25 CL CL2021002248A patent/CL2021002248A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW202045728A (zh) | 2020-12-16 |
| IL285776A (en) | 2021-10-31 |
| KR20210132095A (ko) | 2021-11-03 |
| CN114040980A (zh) | 2022-02-11 |
| WO2020176562A1 (en) | 2020-09-03 |
| CA3130055A1 (en) | 2020-09-03 |
| CL2021002248A1 (es) | 2022-03-04 |
| AU2020229772A1 (en) | 2021-08-26 |
| CO2021011090A2 (es) | 2021-09-09 |
| JP2022525848A (ja) | 2022-05-20 |
| MX2021010266A (es) | 2021-09-23 |
| PE20212072A1 (es) | 2021-10-26 |
| EP3931337A1 (en) | 2022-01-05 |
| US20220118108A1 (en) | 2022-04-21 |
| BR112021016566A2 (pt) | 2021-11-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL273959A (en) | Methods and preparations for the treatment of rare diseases | |
| IL291140A (en) | Preparations and methods for the treatment of inflammatory and immune diseases | |
| IL274578A (en) | Pharmaceutical compounds and preparations thereof for use in the treatment of leiftic diseases | |
| IL287523A (en) | Useful preparations for the treatment of Pompe disease | |
| IL287715A (en) | Useful preparations in the treatment of metachromatic leukodystrophy | |
| IL284414A (en) | Methods and preparations for the treatment of Fabry disease | |
| IL288375A (en) | New compounds and their pharmaceutical preparations for the treatment of diseases | |
| IL282251A (en) | Compositions and methods for treatment of liver disease | |
| IL287796A (en) | Preparations and methods for the treatment of diseases mediated by ATPase | |
| BR112018069682A2 (pt) | métodos de tratamento para doenças colestáticas e fibróticas | |
| GB201907558D0 (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of diseases | |
| IL285776A (en) | Useful preparations in the treatment of Kraba's disease | |
| IL283469A (en) | Inhalable preparations for use in the treatment of lung diseases | |
| IL287797A (en) | Oligosaccharide preparations and methods of use | |
| ZA202107235B (en) | Compositions and methods for treating ocular disease | |
| IL285751A (en) | New compounds and their pharmaceutical preparations for the treatment of diseases | |
| IL272495A (en) | Pharmaceutical compounds and preparations thereof for use in the treatment of leiftic diseases | |
| EP4003381A4 (en) | COMPOSITIONS AND METHODS FOR TREATING SKIN INFECTIONS AND OTHER DISEASES | |
| KR102090101B9 (ko) | 구강 질환 예방 또는 치료용 조성물 | |
| EP3911306C0 (en) | PHMB COMPOSITIONS CONTAINING VASELINE AND METHODS FOR TREATING ONYCHOMYCOSIS | |
| KR102071614B9 (ko) | 6-디아조-5-옥소-l-노르루신을 포함하는 염증성 피부 질환 치료용 약제학적 조성물 | |
| GB201806663D0 (en) | 2-Oxothiazole compositions for treatment of fibrotic disease | |
| GB201817346D0 (en) | Compounds and pharmaceutical compositions thereof for use in the treatment of diseases | |
| EP3932421A4 (en) | COMPOSITION FOR USE IN THE TREATMENT OF ALLERGIC DISEASES | |
| GB201718838D0 (en) | Compounds and pharmaceutical compositions thereof for use in the treatment of fibrotic diseases |